- Home
- FMST vs AKTX Comparison
FMST vs AKTX Comparison
Compare FMST & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMST
- AKTX
- Stock Information
- Founded
- FMST 2005
- AKTX N/A
- Country
- FMST Canada
- AKTX United States
- Employees
- FMST N/A
- AKTX N/A
- Industry
- FMST Other Metals and Minerals
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- FMST Basic Materials
- AKTX Health Care
- Exchange
- FMST Nasdaq
- AKTX Nasdaq
- Market Cap
- FMST 38.2M
- AKTX 35.7M
- IPO Year
- FMST N/A
- AKTX N/A
- Fundamental
- Price
- FMST $2.92
- AKTX $0.79
- Analyst Decision
- FMST
- AKTX Strong Buy
- Analyst Count
- FMST 0
- AKTX 2
- Target Price
- FMST N/A
- AKTX $3.30
- AVG Volume (30 Days)
- FMST 441.0K
- AKTX 91.9K
- Earning Date
- FMST 08-13-2025
- AKTX 08-13-2025
- Dividend Yield
- FMST N/A
- AKTX N/A
- EPS Growth
- FMST N/A
- AKTX N/A
- EPS
- FMST N/A
- AKTX N/A
- Revenue
- FMST N/A
- AKTX N/A
- Revenue This Year
- FMST N/A
- AKTX N/A
- Revenue Next Year
- FMST N/A
- AKTX N/A
- P/E Ratio
- FMST N/A
- AKTX N/A
- Revenue Growth
- FMST N/A
- AKTX N/A
- 52 Week Low
- FMST $0.55
- AKTX $0.57
- 52 Week High
- FMST $5.74
- AKTX $3.85
- Technical
- Relative Strength Index (RSI)
- FMST 47.43
- AKTX 40.50
- Support Level
- FMST $2.96
- AKTX $0.57
- Resistance Level
- FMST $3.24
- AKTX $0.89
- Average True Range (ATR)
- FMST 0.25
- AKTX 0.07
- MACD
- FMST -0.03
- AKTX 0.01
- Stochastic Oscillator
- FMST 14.12
- AKTX 60.72
About FMST Foremost Lithium Resource & Technology Ltd. Common stock
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec. Geographically it covers Canada and United states.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.